Mark Lackner - Jan 2, 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Scientific Officer
Signature: /s/ Andrea Paul, attorney-in-fact for Mark Lackner
Stock symbol: ZNTL
Transactions as of: Jan 2, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/3/2024, 08:21 PM
Previous filing: Jan 3, 2024
Next filing: Feb 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+40K	+245.2%	$0.00	56.3K	Jan 2, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+60K		$0.00	60K	Jan 2, 2024	Common Stock	60K	$15.99	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer.
F2	The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

Content

Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer.

The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.